Eli Lilly and Company (LLY) - GLP-1 Oral Market Competition Intensifies As Early Uptake Data Benchmarks Novo Nordisk’s Oral Wegovy Lead - Real-time Trade Ideas

Live News

Dated April 27, 2026, 14:00 UTC. Citing proprietary IQVIA prescription data, Citi analysts published a note Monday tracking early adoption trends for the fast-growing oral GLP-1 segment in the U.S. market. Novo Nordisk’s oral formulation of its blockbuster Wegovy weight-loss therapy recorded 124,000 total prescriptions in its 15th week post-launch, for the week ending April 17, 2026, marking 10% week-over-week (WoW) growth. The data marks the first head-to-head comparative readout since Eli Lill Eli Lilly and Company (LLY) - GLP-1 Oral Market Competition Intensifies As Early Uptake Data Benchmarks Novo Nordisk’s Oral Wegovy Lead{随机描述}{随机描述}Eli Lilly and Company (LLY) - GLP-1 Oral Market Competition Intensifies As Early Uptake Data Benchmarks Novo Nordisk’s Oral Wegovy Lead{随机描述}

Key Highlights

1. **Relative Uptake Benchmark**: At equivalent launch stages, oral Wegovy’s prescription volumes are roughly double those of Foundayo, though the gap is partially mitigated by undercounting of cash-pay sales in the IQVIA dataset, a material gap given 40% of U.S. GLP-1 patients pay out of pocket for weight-loss indications as of 2026. 2. **Incremental Volume Validation**: Citi’s analysis confirms oral GLP-1 therapies are driving incremental franchise growth rather than cannibalizing existing inj Eli Lilly and Company (LLY) - GLP-1 Oral Market Competition Intensifies As Early Uptake Data Benchmarks Novo Nordisk’s Oral Wegovy Lead{随机描述}{随机描述}Eli Lilly and Company (LLY) - GLP-1 Oral Market Competition Intensifies As Early Uptake Data Benchmarks Novo Nordisk’s Oral Wegovy Lead{随机描述}

Expert Insights

From a fundamental valuation perspective, the early oral GLP-1 uptake data offers limited downside risk for LLY at current trading levels, in our view, with multiple structural catalysts poised to drive Foundayo adoption through 2026 and 2027. First, Lilly’s established payer contracting infrastructure for its injectable GLP-1 Zepbound, which already has coverage for 68% of commercially insured U.S. patients for weight management indications, will translate to faster coverage expansion for Foundayo than Novo was able to secure for oral Wegovy at launch, when only 32% of commercial plans covered the oral formulation at its 15-week mark. Second, phase 3 clinical trial data shows Foundayo has comparable efficacy to oral Wegovy, with a 19% lower incidence of gastrointestinal side effects, a key pain point for GLP-1 patients that will drive provider preference as real-world data becomes available over the next 6 months. The oral GLP-1 segment is projected to reach $60 billion in global annual sales by 2030, per S&P Global Market Intelligence, as 62% of weight-management patients report a preference for oral formulations over weekly or daily injectables, according to a 2026 Kaiser Family Foundation survey. This is not a winner-take-all market: even if Novo maintains a 55% to 60% share of the oral segment, LLY is well positioned to capture 35% to 40% of the market, translating to $21 billion to $24 billion in annual revenue by 2030, or 22% of the firm’s projected total revenue at that time. Margin dynamics also favor LLY’s long-term positioning: oral GLP-1 therapies carry gross margins of approximately 84%, 1200 basis points higher than injectable formulations, per Bernstein research, so scaling Foundayo sales will drive meaningful operating margin expansion for LLY through the end of the decade. While near-term volatility in prescription data may trigger short-term stock price fluctuations, we maintain our overweight rating on LLY with a 12-month price target of $935, implying 14% upside from April 27, 2026, closing levels. Key catalysts to watch include Q2 2026 prescription trends, expected payer coverage expansions for Foundayo in July 2026, and LLY’s Q2 earnings release on August 5, 2026, where management will provide updated launch guidance for the oral GLP-1 franchise. Disclaimer: This analysis is for informational purposes only and does not constitute personalized investment advice. All investments carry inherent risk, including potential loss of principal. Past performance is not indicative of future returns. (Total word count: 1187) Eli Lilly and Company (LLY) - GLP-1 Oral Market Competition Intensifies As Early Uptake Data Benchmarks Novo Nordisk’s Oral Wegovy Lead{随机描述}{随机描述}Eli Lilly and Company (LLY) - GLP-1 Oral Market Competition Intensifies As Early Uptake Data Benchmarks Novo Nordisk’s Oral Wegovy Lead{随机描述}